CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Celldex Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.33B | $166.30M |
| Enterprise Value | $1.61B | $88.19M |
| PS Ratio | 14746.70 | 3.65 |
| PB Ratio | 3.26 | 2.03 |
| P/TBV Ratio | 3.39 | 2.29 |
Enterprise value
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 10205.00 | 2.51 |
Income (trailing twelve months)
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Revenue | $158.00K | $58.34M |
| Operating Income | -$325.83M | -$21.40M |
| Net Income | -$300.55M | -$22.46M |
| EBITDA | -$322.43M | -$16.91M |
Margins
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -206220.0% | -44.0% |
| Profit Margin | -190221.0% | -40.2% |
| EBITDA Margin | -204071.0% | -30.2% |
| FCF Margin | -153231.0% | -9.27% |
Returns
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -43.9% | -53.2% |
| Return on Assets (ROA) | -40.8% | -40.9% |
| Return on Invested Capital (ROIC) | -2335.2% | -32.4% |
| Return on Capital Employed (ROCE) | -45.2% | -38.1% |
Growth
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -97.3% | 5.96% |
| Revenue Growth (3Y CAGR) | -13.1% | 2.25% |
| Revenue Growth (5Y CAGR) | -26.9% | 6.48% |
Balance sheet
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $717.59M | $61.43M |
| Net Cash (Debt) | $717.59M | $15.35M |
| Net Cash Per Share | $9.14 | $0.66 |
| Equity (Book Value) | $714.56M | $49.09M |
| Book Value Per Share | $9.10 | $1.37 |
| Tangible Book Value | $687.37M | $23.52M |
| Working Capital | $663.61M | $76.81M |
Financial position
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 11.82 | 3.34 |
| Quick Ratio | 11.70 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$235.57M | -$12.35M |
| Capital Expenditures | -$6.54M | -$1.08M |
| Free Cash Flow | -$242.11M | -$20.22M |
| FCF Per Share | -$3.08 | -$0.42 |
Efficiency
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $798 | $404.87K |
| Profits Per Employee | -$1.52M | -$703.34K |
| Employee Count | 198 | 74 |
Dividends and yields
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -12.9% | -23.3% |
| FCF Yield | -10.4% | -8.72% |
Shares
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 78,529,500 | 58,127,000 |
| Shares Change (QoQ) | 17.9% | 0.54% |
| Float | 78,206,400 | 49,136,700 |
| Shares Held by Insiders | 0.41% | 11.6% |
| Shares Held by Institutions | 109.3% | 59.4% |
Scores
| Measure | Celldex Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 16.75 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Celldex Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.